Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Please write to us at: Contact@qvents.in
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on other pharma Quality and Regulatory subjects which you would like Qvents to address. Your feedback helps us making and maintaining the Qvents portal as a useful resource for Pharma professionals
You can also write to us on different Quality events (Deviations, OOS, Complaints, CAPAs and so on), Warning letters, 483s, Recalls, Import Alerts, Audit observations) you would like Qvents to initiate posts and discussions. We will review and get back to you, take up the subjects for discussion in Qvents.
Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
The USFDA has issued a Warning Letter to the Indian drug manufacturing facility of Patcos Cosmetics Pvt. Ltd. in Daman (March 2026). In a rare move, the FDA also published photographic evidence of insanitary conditions observed during inspection. USFDA investigators...
Indian pharma major Zydus Lifesciences has received approval from China’s National Medical Products Administration (NMPA) for its novel drug Desidustat for the treatment of anaemia associated with Chronic Kidney Disease (CKD) in March 2026. This marks the second regulatory approval...
The USFDA has Approved the NDA for ADQUEY (Difamilast 1%) ointment for the treatment of atopic dermatitis (eczema) in February 2026. In a press release, Aurobindo Pharma announced the approval of the NDA for ADQUEY by its wholly owned stepdown...
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on Pharma Quality and Regulatory topics and subjects you would like Qvents to cover. Your feedback helps us in making and maintaining the Qvents portal as a useful resource for Pharma TechOps professionals. Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
Please feel free to contact us for any enquiries.
Email: contact@qvents.in
Phone: (+91) 9945519525
We value your feedback on the Posts, Discussions, Information presented by Qvents. Also write to us on Pharma Quality and Regulatory topics and subjects you would like Qvents to cover. Your feedback helps us in making and maintaining the Qvents portal as a useful resource for Pharma TechOps professionals. Please also write to us for general feedback, quality of contents, any irrelevant or offensive posts, threads, comments
Please feel free to contact us for any enquiries.
Email: contact@qvents.in
Phone: (+91) 9945519525
The USFDA has issued a Warning Letter to the Indian drug manufacturing facility of Patcos Cosmetics Pvt. Ltd. in Daman (March 2026). In a rare move, the FDA also published photographic evidence of insanitary conditions observed during inspection. USFDA investigators...
Indian pharma major Zydus Lifesciences has received approval from China’s National Medical Products Administration (NMPA) for its novel drug Desidustat for the treatment of anaemia associated with Chronic Kidney Disease (CKD) in March 2026. This marks the second regulatory approval...
The USFDA has Approved the NDA for ADQUEY (Difamilast 1%) ointment for the treatment of atopic dermatitis (eczema) in February 2026. In a press release, Aurobindo Pharma announced the approval of the NDA for ADQUEY by its wholly owned stepdown...
